HORMONAL PROFILES IN POSTMENOPAUSAL WOMEN AFTER THERAPY WITH SUBCUTANEOUS IMPLANTS

Plasma hormones were estimated in 24 postmenopausal patients who had been castrated. Each was given a sub‐cutaneous implant of either 100 mg or 50 mg of oestradiol, or 50 mg of oestradiol with 100 mg of testosterone, or 200 mg of testosterone. Plasma hormone estimations were repeated at two weeks, one month and then monthly for up to 12 months. Plasma follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations were seen to fall at two weeks after all implants containing oestradiol. Plasma testosterone concentrations rose from a mean concentration of 1.0 nmol/1 to 5.0 nmol/1 and 6.7 nmol/1 after implants of 100 mg and 200 mg of testosterone respectively. Implants containing oestradiol caused the pretreatment ratio of the concentrations of oestrone to oestradiol to change from 2:1 to 1:2. The implant of 100 mg of oestradiol caused the plasma oestradiol concentration to rise to a mean value of 602.3 pmol/1 and those of oestrone to rise to 356.7 pmol/1. The more commonly used implants contain 50 mg of oestradiol and these caused the mean concentration of plasma oestradiol to rise to 346.7 pmol/1 and oestrone to rise to 233.9 pmol/1. These values compare favourably with those attained after oral oestrogen therapy.

[1]  J. Studd,et al.  Procedures in practice. Hormone implantation. , 1980, British medical journal.

[2]  J. Studd,et al.  PREVENTION AND TREATMENT OF ENDOMETRIAL DISEASE IN CLIMACTERIC WOMEN RECEIVING ŒSTROGEN THERAPY , 1979, The Lancet.

[3]  W. Collins,et al.  Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause. , 1979, British medical journal.

[4]  J. Studd,et al.  Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. , 1979, Lancet.

[5]  S. Campbell,et al.  Clinical considerations in the management of the menopause: the endometrium. , 1978, Postgraduate medical journal.

[6]  W. Collins,et al.  ENDOCRINE CHANGES AND SYMPTOMATOLOGY AFTER OOPHORECTOMY IN PREMENOPAUSAL WOMEN , 1977, British journal of obstetrics and gynaecology.

[7]  H. Jacobs,et al.  PLASMA HORMONE PROFILES IN POST‐MENOPAUSAL WOMEN BEFORE AND DURING OESTROGEN THERAPY , 1977 .

[8]  W. Collins,et al.  OESTRADIOL AND TESTOSTERONE IMPLANTS IN THE TREATMENT OF PSYCHOSEXUAL PROBLEMS IN THE POST‐MENOPAUSAL WOMAN , 1977 .

[9]  W. Collins,et al.  Hormonal profiles after the menopause. , 1976, British medical journal.

[10]  A. Vermeulen.  The hormonal activity of the postmenopausal ovary. , 1976, The Journal of clinical endocrinology and metabolism.

[11]  P. Siiteri.  Post-menopausal estrogen production. , 1975, Frontiers of hormone research.

[12]  P. Siiteri,et al.  The relationship between the extraglandular production of estrone and the occurrence of endometrial neoplasia. , 1974, Gynecologic oncology.

[13]  C. Longcope.  Metabolic clearance and blood production rates of estrogens in postmenopausal women. , 1971, American journal of obstetrics and gynecology.

[14]  P. Siiteri,et al.  Plasma precursors of estrogen. I. Extent of conversion of plasma delta-4-androstenedione to estrone in normal males and nonpregnant normal, castrate and adrenalectomized females. , 1967, The Journal of clinical endocrinology and metabolism.

[15]  S. Yrarrázaval,et al.  [The climacteric]. , 1957, Revista medica de Chile.

[16]  K. Ryan,et al.  The interconversion of estrone and estradiol by human tissue slices. , 1953, Endocrinology.

[17]  R. Greenblatt,et al.  Indications for hormonal pellets in the therapy of endocrine and gynecic disorders. , 1949, American journal of obstetrics and gynecology.

[18]  D. Moore.  Nutritional Disturbances and Optic Atrophy , 1940 .